Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Koopman

Showing results (181-190 of 193) with videos related to

Pageof 20
Sort By:
Genome Medicine|August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYDJonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
Endoscopy|February 7, 2024
Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancersLisa van der Schee, Krijn J C Haasnoot, Sjoerd G Elias, et al.
JNCI Cancer Spectrum|December 15, 2025
Physical activity patterns after diagnosis and survival of prognostic colorectal cancer subgroupsKarel C Smit, Jeroen W G Derksen, Anne-Sophie van Lanen, et al.
Journal of Clinical Epidemiology|March 25, 2026
Learning from every patient: the 'outpatient innovation clinic'Maarten J Kamphuis, Irene C van der Schaaf, Roxanne Gal, et al.
Nature|May 31, 2019
Genome-wide cell-free DNA fragmentation in patients with cancerStephen Cristiano, Alessandro Leal, Jillian Phallen, et al.
The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
JAMA Surgery|May 19, 2021
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical TrialKoen P Rovers, Checca Bakkers, Simon W Nienhuijs, et al.
The British Journal of Surgery|January 9, 2026
Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 studyCarmen Rubio-Alarcón, Andrew Georgiadis, Ingrid A Franken, et al.
Medicine and Science in Sports and Exercise|December 11, 2023
Determinants of Physical Activity among Patients with Colorectal Cancer: From Diagnosis to 5 Years after DiagnosisKarel C Smit, Jeroen W G Derksen, Rebecca K Stellato, et al.
Pageof 20

Showing results (181-190 of 193) with videos related to

Sort By:
Pageof 20
Genome Medicine|August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYDJonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
Endoscopy|February 7, 2024
Oncologic outcomes of screen-detected and non-screen-detected T1 colorectal cancersLisa van der Schee, Krijn J C Haasnoot, Sjoerd G Elias, et al.
JNCI Cancer Spectrum|December 15, 2025
Physical activity patterns after diagnosis and survival of prognostic colorectal cancer subgroupsKarel C Smit, Jeroen W G Derksen, Anne-Sophie van Lanen, et al.
Journal of Clinical Epidemiology|March 25, 2026
Learning from every patient: the 'outpatient innovation clinic'Maarten J Kamphuis, Irene C van der Schaaf, Roxanne Gal, et al.
Nature|May 31, 2019
Genome-wide cell-free DNA fragmentation in patients with cancerStephen Cristiano, Alessandro Leal, Jillian Phallen, et al.
The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
JAMA Surgery|May 19, 2021
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical TrialKoen P Rovers, Checca Bakkers, Simon W Nienhuijs, et al.
The British Journal of Surgery|January 9, 2026
Circulating tumour DNA in patients with stage III colon cancer: multicentre prospective PROVENC3 studyCarmen Rubio-Alarcón, Andrew Georgiadis, Ingrid A Franken, et al.
Medicine and Science in Sports and Exercise|December 11, 2023
Determinants of Physical Activity among Patients with Colorectal Cancer: From Diagnosis to 5 Years after DiagnosisKarel C Smit, Jeroen W G Derksen, Rebecca K Stellato, et al.
Pageof 20